Bicycle Therapeutics Limited SEC Filings

Bicycle Therapeutics plc (BCYC) – Form 4 insider transaction

Chief Operating Officer Alistair Milnes disclosed two small open-market sales of ordinary shares linked to the automatic “sell-to-cover” feature of recently vested restricted stock units (RSUs):

• 2 July 2025: 1,149 shares sold at a weighted-average price of $7.09.
• 3 July 2025: 966 shares sold at a weighted-average price of $7.44.

The combined disposition totals 2,115 shares, representing roughly 2% of the executive’s pre-sale position. After the transactions Milnes still beneficially owns 95,502 ordinary shares. Footnote disclosures confirm the sales were not discretionary; they were required to satisfy minimum statutory withholding taxes owed on RSU vesting.

No derivative securities were involved, and there is no indication of additional insider activity. Given the modest size and tax-related nature of the sale, the filing is unlikely to signal a change in the executive’s outlook or the company’s fundamentals.

Bicycle Therapeutics plc (BCYC) – Form 4 insider transaction

Chief Operating Officer Alistair Milnes disclosed two small open-market sales of ordinary shares linked to the automatic “sell-to-cover” feature of recently vested restricted stock units (RSUs):

• 2 July 2025: 1,149 shares sold at a weighted-average price of $7.09.
• 3 July 2025: 966 shares sold at a weighted-average price of $7.44.

The combined disposition totals 2,115 shares, representing roughly 2% of the executive’s pre-sale position. After the transactions Milnes still beneficially owns 95,502 ordinary shares. Footnote disclosures confirm the sales were not discretionary; they were required to satisfy minimum statutory withholding taxes owed on RSU vesting.

No derivative securities were involved, and there is no indication of additional insider activity. Given the modest size and tax-related nature of the sale, the filing is unlikely to signal a change in the executive’s outlook or the company’s fundamentals.

Bicycle Therapeutics plc (BCYC) – Form 4 insider transaction

Chief Operating Officer Alistair Milnes disclosed two small open-market sales of ordinary shares linked to the automatic “sell-to-cover” feature of recently vested restricted stock units (RSUs):

• 2 July 2025: 1,149 shares sold at a weighted-average price of $7.09.
• 3 July 2025: 966 shares sold at a weighted-average price of $7.44.

The combined disposition totals 2,115 shares, representing roughly 2% of the executive’s pre-sale position. After the transactions Milnes still beneficially owns 95,502 ordinary shares. Footnote disclosures confirm the sales were not discretionary; they were required to satisfy minimum statutory withholding taxes owed on RSU vesting.

No derivative securities were involved, and there is no indication of additional insider activity. Given the modest size and tax-related nature of the sale, the filing is unlikely to signal a change in the executive’s outlook or the company’s fundamentals.

Bicycle Therapeutics plc (BCYC) – Form 4 insider transaction

Chief Operating Officer Alistair Milnes disclosed two small open-market sales of ordinary shares linked to the automatic “sell-to-cover” feature of recently vested restricted stock units (RSUs):

• 2 July 2025: 1,149 shares sold at a weighted-average price of $7.09.
• 3 July 2025: 966 shares sold at a weighted-average price of $7.44.

The combined disposition totals 2,115 shares, representing roughly 2% of the executive’s pre-sale position. After the transactions Milnes still beneficially owns 95,502 ordinary shares. Footnote disclosures confirm the sales were not discretionary; they were required to satisfy minimum statutory withholding taxes owed on RSU vesting.

No derivative securities were involved, and there is no indication of additional insider activity. Given the modest size and tax-related nature of the sale, the filing is unlikely to signal a change in the executive’s outlook or the company’s fundamentals.

Bicycle Therapeutics plc (BCYC) – Form 4 insider transaction

Chief Operating Officer Alistair Milnes disclosed two small open-market sales of ordinary shares linked to the automatic “sell-to-cover” feature of recently vested restricted stock units (RSUs):

• 2 July 2025: 1,149 shares sold at a weighted-average price of $7.09.
• 3 July 2025: 966 shares sold at a weighted-average price of $7.44.

The combined disposition totals 2,115 shares, representing roughly 2% of the executive’s pre-sale position. After the transactions Milnes still beneficially owns 95,502 ordinary shares. Footnote disclosures confirm the sales were not discretionary; they were required to satisfy minimum statutory withholding taxes owed on RSU vesting.

No derivative securities were involved, and there is no indication of additional insider activity. Given the modest size and tax-related nature of the sale, the filing is unlikely to signal a change in the executive’s outlook or the company’s fundamentals.

SEC Form 4 filed for First Guaranty Bancshares, Inc. (FGBI) discloses that director Edgar R. Smith III markedly increased his ownership on 30 June 2025.

• Open-market purchase: 30,865 common shares acquired at $8.10 (Code P).
• Debt-for-equity exchange: 1,981,506 new shares issued at $7.57 in exchange for a $15 million floating-rate subordinated note under an Exchange Agreement dated 16 June 2025.
• Note amendments: 88,482 shares issued at $8.00 to Smith & Tate Investments, LLC pursuant to amendments to an existing promissory note and a subordinated note.

Following these transactions, Smith reports 2,852,467 shares held directly. Indirectly, he controls additional positions through several LLCs, including Smith & Hood Holding Company, LLC (1,062,817 shares) and three other investment entities, taking total reported beneficial ownership well above three million shares.

The filing signals a net addition of roughly 2.1 million shares, replacing interest-bearing debt with equity and reflecting continued insider confidence. Because the new shares were issued below recent market purchases ($7.57 vs. $8.10), the company reduces debt at a valuation apparently acceptable to both parties while the director deepens alignment with common shareholders.

Arhaus, Inc. (NASDAQ: ARHS) filed an 8-K announcing a board change. On 27 June 2025 the Board appointed Samir Desai—currently EVP & Chief Digital and Technology Officer at Abercrombie & Fitch—as an independent Class III director. His initial term runs until the 2027 annual meeting, after which he is expected to stand for re-election. Desai will sit on the Board’s Technology Committee, bringing extensive omnichannel retail and IT leadership experience from Abercrombie & Fitch, Equinox Group and Intertex Apparel Group. To accommodate the appointment, the Board’s size rises from ten to eleven directors. Compensation will mirror that of Arhaus’s other non-employee directors and no related-party transactions were reported. Exhibit 104 (Inline XBRL cover page) accompanies the filing.

Form 4 filing for UnitedHealth Group (UNH) dated 07/02/2025 discloses routine quarterly equity compensation to non-employee director Paul R. Garcia.

• Transactions (07/01/2025): 173 deferred stock units (immediately vested, must be held until board service ends) and 96 shares of common stock, both awarded at $0 cost.
• Post-transaction ownership: 2,750 common shares held directly; 2,146 shares in a revocable trust; 45 and 55 shares in two additional trusts, for a total indirect holding of 2,246 shares.
• No derivative securities were acquired or disposed of; the filing cites the awards as regular quarterly director compensation, not incentive-based or market purchases.

The filing is administrative in nature, with no impact on company operations, capital structure, or insider sentiment beyond customary board compensation.

Triumph Financial, Inc. (TFIN) – Form 4 insider filing

Director Laura Easley reported the July 1, 2025 receipt of 653 fully-vested common shares granted under the company’s 2014 Omnibus Incentive Plan. The award was recorded at $0 cost, indicating a standard equity compensation grant rather than an open-market purchase. Following the transaction, Easley’s direct holdings rose to 8,301 shares. She also reports 1,895 shares held indirectly as trustee of the Easley Family Trust, for total beneficial ownership of 10,196 shares.

No derivative securities were involved, and there were no dispositions. This filing reflects routine board-level compensation and represents a modest increase in insider ownership (approximately 0.04% of TFIN’s 25 million share count, assuming prior public float). While not financially material to the company, insider accumulation can be viewed as a modestly positive governance signal.